Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Therapy in prion diseases: from molecular and cellular biology to therapeutic targets.

Krammer C, Vorberg I, Schätzl HM, Gilch S.

Infect Disord Drug Targets. 2009 Feb;9(1):3-14.

PMID:
19200010
2.

Targeting prion proteins in neurodegenerative disease.

Gilch S, Krammer C, Schätzl HM.

Expert Opin Biol Ther. 2008 Jul;8(7):923-40. doi: 10.1517/14712598.8.7.923 . Review.

PMID:
18549323
3.

Prion diseases: from molecular biology to intervention strategies.

Nunziante M, Gilch S, Schätzl HM.

Chembiochem. 2003 Dec 5;4(12):1268-84. Review.

PMID:
14661267
4.

Prion protein self-interactions: a gateway to novel therapeutic strategies?

Rigter A, Langeveld JP, van Zijderveld FG, Bossers A.

Vaccine. 2010 Nov 16;28(49):7810-23. doi: 10.1016/j.vaccine.2010.09.012. Epub 2010 Oct 20. Review.

PMID:
20932496
5.

Aptamers against prion proteins and prions.

Gilch S, Schätzl HM.

Cell Mol Life Sci. 2009 Aug;66(15):2445-55. doi: 10.1007/s00018-009-0031-5. Epub 2009 Apr 25. Review.

PMID:
19396399
6.

Gene and cell therapy for prion diseases.

Relaño-Ginés A, Gabelle A, Lehmann S, Milhavet O, Crozet C.

Infect Disord Drug Targets. 2009 Feb;9(1):58-68. Review.

PMID:
19200016
7.

The molecular biology of prion propagation.

Clarke AR, Jackson GS, Collinge J.

Philos Trans R Soc Lond B Biol Sci. 2001 Feb 28;356(1406):185-95. Review.

8.

Recent advances in prion biology.

Aguzzi A, Miele G.

Curr Opin Neurol. 2004 Jun;17(3):337-42. Review.

PMID:
15167069
9.

Evolving views in prion glycosylation: functional and pathological implications.

Ermonval M, Mouillet-Richard S, Codogno P, Kellermann O, Botti J.

Biochimie. 2003 Jan-Feb;85(1-2):33-45. Review.

PMID:
12765773
10.

Promising developments bringing prion diseases closer to therapy and prophylaxis.

Gilch S, Schätzl HM.

Trends Mol Med. 2003 Sep;9(9):367-9. Review.

PMID:
13129701
11.

Therapeutic approaches targeting the prion receptor LRP/LR.

Zuber C, Ludewigs H, Weiss S.

Vet Microbiol. 2007 Aug 31;123(4):387-93. Epub 2007 Apr 8. Review.

PMID:
17498894
12.

Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.

Kim Y, Han B, Titlow W, Mays CE, Kwon M, Ryou C.

Antiviral Res. 2009 Nov;84(2):185-93. doi: 10.1016/j.antiviral.2009.09.002. Epub 2009 Sep 11.

PMID:
19748523
13.

Development of antibody fragments for immunotherapy of prion diseases.

Campana V, Zentilin L, Mirabile I, Kranjc A, Casanova P, Giacca M, Prusiner SB, Legname G, Zurzolo C.

Biochem J. 2009 Mar 15;418(3):507-15. doi: 10.1042/BJ20081541.

PMID:
19000036
14.

Molecular approaches to mechanisms of prion diseases.

Bratosiewicz-Wasik J, Wasik TJ, Liberski PP.

Folia Neuropathol. 2004;42 Suppl A:33-46. Review.

PMID:
15449458
15.

The pathogenic mechanisms of prion diseases.

Unterberger U, Voigtländer T.

CNS Neurol Disord Drug Targets. 2007 Dec;6(6):424-55. Review.

PMID:
18220781
16.

Prion protein functions and dysfunction in prion diseases.

Sakudo A, Ikuta K.

Curr Med Chem. 2009;16(3):380-9. Review.

PMID:
19149584
17.

Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy.

Vana K, Zuber C, Nikles D, Weiss S.

Cell Mol Neurobiol. 2007 Feb;27(1):107-28. Epub 2006 Dec 7. Review.

PMID:
17151946
18.

Metabolic aspects of prion diseases: an overview.

Vranac T, Bresjanac M.

Curr Drug Targets. 2010 Oct;11(10):1207-17. Review.

PMID:
20840065
19.

Understanding the natural variability of prion diseases.

Geissen M, Krasemann S, Matschke J, Glatzel M.

Vaccine. 2007 Jul 26;25(30):5631-6. Epub 2007 Mar 7. Review.

PMID:
17391814
20.

Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation.

Gilch S, Nunziante M, Ertmer A, Schätzl HM.

Vet Microbiol. 2007 Aug 31;123(4):377-86. Epub 2007 Apr 8. Review.

PMID:
17493775
Items per page

Supplemental Content

Write to the Help Desk